Oncotelic Therapeutics, Inc.
OTLC
$0.03
$0.001.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6,403.68% | 5,704.68% | 5,610.29% | 64.17% | -216.83% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 315.26% | 147.80% | 62.24% | -66.44% | -33.79% |
| Total Other Non-Cash Items | -8,919.38% | -7,678.30% | -7,675.01% | -90.52% | 4,896.47% |
| Change in Net Operating Assets | -105.78% | -131.70% | -69.46% | 488.78% | 640.31% |
| Cash from Operations | -182.14% | -130.57% | -86.84% | 30.22% | 51.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 196.55% | 181.43% | 111.27% | 5.36% | -50.13% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 191.82% | 172.60% | 111.27% | 8.31% | -44.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 524.84% | 85.90% | 103.20% | 318.40% | 114.32% |